Fibrogen Company Profile

09:03 EST 18th November 2017 | BioPortfolio

Extracellular matrix biology to discover and develop innovative therapies for fibroproliferative disorders - organ fibrosis, tissue repair and regeneration.


225 Gateway Boulevard
South San Francisco
United States of America


Phone: 415 635 1500
Fax: 650 866 7204

News Articles [44 Associated News Articles listed on BioPortfolio]

FibroGen Says CFDA Accepts Novel Anemia NDA for Review

FibroGen, a US-China biopharma, reported the CFDA has accepted an NDA to review its novel anemia treatment for China approval. Roxadustat is a first-in-class oral treatment for anemia in patients unde...

FibroGen nets $309.7mm via FOPO

FibroGen Inc. (developing therapies for anemia, fibrotic disease, and cancer) netted $309.7mm through a follow-on offering of 8mm common shares at $40.75 each. The company will use some of the funds f...

Galapagos and FibroGen drugs offer hope in IPF

Two biotechs have offered hope to people with idiopathic pulmonary fibrosis with results from two mid-stage drugs. Belgian biotech Galapagos and US-based FibroGen have both published mid-stage data s...

FibroGen Hails 'Milestone' IPF Data, Phase III And Partners Beckon

Phase II data for FibroGen's first-in-class therapy for idiopathic pulmonary fibrosis panrevlumab has sent its shares soaring and could have...   

FDA grants orphan status to FibroGen's pancreatic cancer drug

The FDA has given orphan drug designation to FibroGen's pamrevlumab, a treatment for patients with pancreatic cancer. -More- 

FibroGen’s Pamrevlumab Succeeds in Mid-Stage Idiopathic Pulmonary Fibrosis Study

SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today positive topline results from the company’s Phase ...

FibroGen's pamrevlumab meets in Phase II for IPF

FibroGen raises $326M in follow-on

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Single compassionate use subject is an 83 year old woman with a history of lymph node positive breast cancer and recently diagnosed pancreatic cancer in May. With an Eastern Cooperative On...

Companies [2 Associated Companies listed on BioPortfolio]

FibroGen, Inc.

FibroGen, Inc. is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible ...


Extracellular matrix biology to discover and develop innovative therapies for fibroproliferative disorders - organ fibrosis, tissue repair and regeneration.

More Information about "Fibrogen" on BioPortfolio

We have published hundreds of Fibrogen news stories on BioPortfolio along with dozens of Fibrogen Clinical Trials and PubMed Articles about Fibrogen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fibrogen Companies in our database. You can also find out about relevant Fibrogen Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record